Stereotaxis

Stereotaxis

Stereotaxis develops robotic cardiology instrument navigation systems that enhances the treatment of arrhythmias and coronary diseases. Learn more

Launch date
Employees
Market cap
CAD254m
Enterprise valuation
CAD249m (Public information from Sep 2024)
Saint-Louis Département de Saint-Louis (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues26.6m35.0m28.1m26.8m26.6m41.3m67.1m
% growth(8 %)32 %(20 %)(5 %)(1 %)56 %62 %
EBITDA(6.7m)(15.1m)(18.8m)(21.2m)(10.4m)(7.1m)2.8m
% EBITDA margin(25 %)(43 %)(67 %)(79 %)(39 %)(17 %)4 %
Profit(6.6m)(10.7m)(18.3m)(20.7m)(20.3m)(16.0m)(9.4m)
% profit margin(25 %)(31 %)(65 %)(77 %)(77 %)(39 %)(14 %)
EV / revenue13.2x13.1x5.5x4.9x7.3x4.7x2.9x
EV / EBITDA-52.3x-30.5x-8.3x-6.2x-18.6x-27.3x69.3x
R&D budget8.1m10.2m10.6m10.3m---
R&D % of revenue31 %29 %38 %38 %---
  • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

Debt

$20.0m

Early VC
N/A

$16.0m

Early VC
N/A

N/A

IPO
N/A

$10.0m

Post IPO Equity
N/A

$24.0m

Post IPO Equity
N/A

$10.0m

Post IPO Equity
*

$25.0m

Post IPO Equity
Total FundingCAD49.1m

Recent News about Stereotaxis

Edit
More about Stereotaxisinfo icon
Edit

Stereotaxis is a leading MedTech company specializing in innovative robotic technologies for the treatment of arrhythmias. The company operates in the healthcare sector, providing advanced robotic catheter ablation systems that enable precise and safe treatment of heart rhythm disorders. Stereotaxis primarily serves healthcare professionals, including physicians and hospitals, who are involved in the treatment of arrhythmias. The company’s business model revolves around the development, manufacturing, and sale of its robotic systems, as well as providing ongoing support and maintenance services. Revenue is generated through the sale of these systems and associated services. Stereotaxis is recognized for its Robotic Magnetic Navigation (RMN) System, which has been successfully implemented in various healthcare facilities, enhancing the precision and safety of arrhythmia treatments. The company continues to innovate and expand its market presence, aiming to improve patient outcomes and advance the field of endovascular treatment.

Keywords: Robotic Catheter Ablation, Arrhythmia Treatment, MedTech, Healthcare, Precision, Safety, Physicians, Hospitals, RMN System, Endovascular Treatment.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Stereotaxis

Edit
Access Point Technologies EP
ACQUISITION by Stereotaxis May 2024